{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:45:40Z","timestamp":1791895540690,"version":"4.3.4"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001502","name":"India Department of Atomic Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001502","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000085","name":"Directorate for Geosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.heliyon.2024.e27011","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T04:52:49Z","timestamp":1709182369000},"page":"e27011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Txnrd1 as a prognosticator for recurrence, metastasis and response to neoadjuvant chemotherapy and radiotherapy in breast cancer patients"],"prefix":"10.1016","volume":"10","author":[{"given":"Raghavendra S.","family":"Patwardhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archita","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh K.","family":"Sandur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2797-4158","authenticated-orcid":false,"given":"Sejal","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e27011_bib1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1634\/theoncologist.2014-0372","article-title":"Defining breast cancer intrinsic subtypes by quantitative receptor expression","volume":"20","author":"Cheang","year":"2015","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib2","series-title":"Cancer Statistics","author":"Siegel","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e27011_bib3","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa050518","article-title":"Effect of screening and adjuvant therapy on mortality from breast cancer","volume":"353","author":"Berry","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27011_bib4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/cncr.25679","article-title":"Update on mammography trends: comparisons of rates in 2000, 2005, and 2008","volume":"117","author":"Breen","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.heliyon.2024.e27011_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJMsr070105","article-title":"The decrease in breast-cancer incidence in 2003 in the United States","volume":"356","author":"Ravdin","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27011_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/1055-9965.EPI-18-0098","article-title":"Proportion of US trends in breast cancer incidence attributable to long-term changes in risk factor distributions","volume":"27","author":"Pfeiffer","year":"2018","journal-title":"Cancer Epidemiology and Prevention Biomarkers"},{"key":"10.1016\/j.heliyon.2024.e27011_bib7","first-page":"363","article-title":"Cancer treatment and survivorship statistics","volume":"69","author":"Miller","year":"2019","journal-title":"CA: a cancer journal for clinicians 2019"},{"key":"10.1016\/j.heliyon.2024.e27011_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JOP.2017.023333","article-title":"Triple-negative breast cancer: current practice and future directions","volume":"13","author":"Costa","year":"2017","journal-title":"Journal of oncology practice"},{"key":"10.1016\/j.heliyon.2024.e27011_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120832","article-title":"Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval","volume":"10","author":"Witteveen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27011_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","article-title":"Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer'","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5710-5","article-title":"Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis\u2013results from a registry-based study from Germany","volume":"19","author":"Holleczek","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e27011_bib12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1200\/JCO.2003.03.130","article-title":"Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII","volume":"21","author":"Wallgren","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-08053-5","article-title":"Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer","volume":"10","author":"Ferreira","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e27011_bib14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27011_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e27011_bib16","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2015.5805","article-title":"Postoperative radiotherapy after breast-conserving surgery for early-stage breast cancer: a review","volume":"2","author":"Speers","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib17","first-page":"371","article-title":"Updates in the treatment of breast cancer with radiotherapy","volume":"26","author":"Castaneda","year":"2017","journal-title":"Surgical Oncology Clinics"},{"key":"10.1016\/j.heliyon.2024.e27011_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-017-0870-1","article-title":"Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival","volume":"19","author":"Poleszczuk","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib19","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","author":"McGale","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e27011_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotobiol.2020.112080","article-title":"Oxidative stress associated metabolic adaptations regulate radioresistance in human lung cancer cells","volume":"213","author":"Singh","year":"2020","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib21","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1002\/cam4.3523","article-title":"Identification of a 9\u2010gene prognostic signature for breast cancer","volume":"9","author":"Tian","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.heliyon.2024.e27011_bib22","first-page":"1","article-title":"A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients","volume":"5","author":"Sun","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e27011_bib23","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1078-0432.CCR-07-1833","article-title":"A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer","volume":"14","author":"Chanrion","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib24","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3109\/10715762.2015.1056180","article-title":"Spatio-temporal changes in glutathione and thioredoxin redox couples during ionizing radiation-induced oxidative stress regulate tumor radio-resistance","volume":"49","author":"Patwardhan","year":"2015","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065929","article-title":"Involvement of ERK-Nrf-2 signaling in ionizing radiation induced cell death in normal and tumor cells","volume":"8","author":"Patwardhan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27011_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120181","article-title":"Pre-clinical evaluation of an innovative oral nano-formulation of baicalein for modulation of radiation responses","volume":"595","author":"Joshi","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.heliyon.2024.e27011_bib27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00280-019-03869-4","article-title":"The role of thioredoxin system in cancer: strategy for cancer therapy","volume":"84","author":"Jia","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib28","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.freeradbiomed.2017.12.029","article-title":"The A to Z of modulated cell patterning by mammalian thioredoxin reductases","volume":"115","author":"Dagnell","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.heliyon.2024.e27011_bib29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17460441.2022.2045270","article-title":"Novel strategies for targeting the thioredoxin system for cancer therapy","volume":"17","author":"Xu","year":"2022","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e27011_bib30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-019-03912-4","article-title":"The thioredoxin system and cancer therapy: a review","volume":"84","author":"Mohammadi","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-pharmtox-052220-102509","article-title":"Thioredoxin reductase inhibition for cancer therapy","volume":"62","author":"Gencheva","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101341","article-title":"Thioredoxin reductase: an emerging pharmacologic target for radiosensitization of cancer","volume":"17","author":"Patwardhan","year":"2022","journal-title":"Translational Oncology"},{"key":"10.1016\/j.heliyon.2024.e27011_bib33","series-title":"UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses","author":"Chandrashekar","year":"2017"},{"key":"10.1016\/j.heliyon.2024.e27011_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: an update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.heliyon.2024.e27011_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep36860","article-title":"Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress","volume":"6","author":"Dong","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e27011_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr2599","article-title":"Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer","volume":"12","author":"Cadenas","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.redox.2015.12.004","article-title":"The thioredoxin system in breast cancer cell invasion and migration","volume":"8","author":"Bhatia","year":"2016","journal-title":"Redox Biol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e27011_bib39","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000050315","article-title":"On the problem of using \u2018optimal\u2019cutpoints in the assessment of quantitative prognostic factors","volume":"24","author":"Holl\u00e4nder","year":"2001","journal-title":"Oncol. Res. Treat."},{"key":"10.1016\/j.heliyon.2024.e27011_bib40","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/jnci\/86.11.829","article-title":"Dangers of using \u201coptimal\u201d cutpoints in the evaluation of prognostic factors","volume":"86","author":"Altman","year":"1994","journal-title":"JNCI (J. Natl. Cancer Inst.): J. Natl. Cancer Inst."},{"key":"10.1016\/j.heliyon.2024.e27011_bib41","series-title":"Statistical Methods for Determining Single or Multiple Cutpoints of Risk Factors in Survival Data Analysis","author":"Kuo","year":"1997"},{"key":"10.1016\/j.heliyon.2024.e27011_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27011_bib43","first-page":"1","article-title":"Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer","volume":"12","author":"Lee","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e27011_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/bioinformatics\/19.2.185","article-title":"A comparison of normalization methods for high density oligonucleotide array data based on variance and bias","volume":"19","author":"Bolstad","year":"2003","journal-title":"Bioinformatics"},{"key":"10.1016\/j.heliyon.2024.e27011_bib45","first-page":"17","article-title":"Outlier resistance, standardization, and modeling issues for DNA microarray data","author":"Amaratunga","year":"2001","journal-title":"Statistics in Genetics and in the Environmental Sciences"},{"key":"10.1016\/j.heliyon.2024.e27011_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.21873\/cgp.20130","article-title":"Gene expression profiles induced by high-dose ionizing radiation in MDA-MB-231 triple-negative breast cancer cell line","volume":"16","author":"Bravata","year":"2019","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.heliyon.2024.e27011_bib47","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.3390\/ijms21134777","article-title":"NRF2, a transcription factor for stress response and beyond","volume":"21","author":"He","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e27011_bib48","series-title":"Breast Cancer Facts & Figures 2019\u20132020","first-page":"1","author":"Society","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e27011_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00280-004-0833-y","article-title":"Redox-cycling of anthracyclines by thioredoxin system: increased superoxide generation and DNA damage","volume":"54","author":"Ravi","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib50","doi-asserted-by":"crossref","first-page":"40084","DOI":"10.1074\/jbc.M507192200","article-title":"Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells","volume":"280","author":"Ravi","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e27011_bib51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12012-020-09605-2","article-title":"Thioredoxin decreases anthracycline cardiotoxicity, but sensitizes cancer cell apoptosis","volume":"21","author":"Das","year":"2021","journal-title":"Cardiovasc. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib52","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Darby","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e27011_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3747\/co.21.2043","article-title":"Concurrent chemoradiotherapy for locally advanced breast cancer\u2014time for a new paradigm?","volume":"22","author":"Mandilaras","year":"2015","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21873\/anticanres.14746","article-title":"Chemoradiotherapy in cancer treatment: rationale and clinical applications","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib55","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/antiox10111733","article-title":"Chlorophyllin inhibits mammalian thioredoxin reductase 1 and triggers cancer cell death","volume":"10","author":"Sun","year":"2021","journal-title":"Antioxidants"},{"key":"10.1016\/j.heliyon.2024.e27011_bib56","unstructured":"Sharma D., Sandur S.K., Checker R., Patwardhan R.S., Gota V.P., Sundarraj J., et al., US-10183026-B2 (2019). PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Patent Summary for US-10183026-B2; [cited 2024 Mar. 4]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/patent\/US-10183026-B2."},{"key":"10.1016\/j.heliyon.2024.e27011_bib57","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s10637-021-01106-5","article-title":"Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer","volume":"39","author":"Abdullah","year":"2021","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.heliyon.2024.e27011_bib58","article-title":"Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e27011_bib59","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e27011_bib60","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e27011_bib61","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1158\/0008-5472.CAN-07-5206","article-title":"The humoral immune system has a key prognostic impact in node-negative breast cancer","volume":"68","author":"Schmidt","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib62","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(05)17947-1","article-title":"Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer","volume":"365","author":"Wang","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e27011_bib63","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1078-0432.CCR-07-1833","article-title":"A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer","volume":"14","author":"Chanrion","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib64","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib65","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/bcr2635","article-title":"Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer","volume":"12","author":"Prat","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027656","article-title":"Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer","volume":"6","author":"Sabatier","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27011_bib67","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1158\/0008-5472.CAN-11-0489","article-title":"microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer","volume":"71","author":"Buffa","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib68","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s10549-011-1895-2","article-title":"Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657)","volume":"132","author":"Esserman","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.heliyon.2024.e27011_bib69","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1158\/1078-0432.CCR-11-1954","article-title":"Search for a gene expression signature of breast cancer local recurrence in young women","volume":"18","author":"Servant","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib70","doi-asserted-by":"crossref","first-page":"R34","DOI":"10.1186\/bcr1997","article-title":"Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy","volume":"10","author":"Nimeus-Malmstrom","year":"2008","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib71","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1158\/0008-5472.CAN-14-0673","article-title":"Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival","volume":"76","author":"den Hollander","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s42003-020-0884-6","article-title":"DNA copy number motifs are strong and independent predictors of survival in breast cancer","volume":"3","author":"Pladsen","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib73","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13058-018-0978-y","article-title":"Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors","volume":"20","author":"Sjostrom","year":"2018","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib74","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41416-021-01630-4","article-title":"Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up","volume":"126","author":"Tutzauer","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e27011_bib75","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41523-021-00337-2","article-title":"Ganitumab and metformin plus standard neoadjuvant therapy in stage 2\/3 breast cancer","volume":"7","author":"Yee","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.heliyon.2024.e27011_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.stemcr.2014.12.007","article-title":"Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response","volume":"4","author":"Chapellier","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e27011_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049529","article-title":"A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27011_bib78","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1158\/1078-0432.CCR-12-1359","article-title":"Biomarker analysis of neoadjuvant doxorubicin\/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer","volume":"19","author":"Horak","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib79","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13058-015-0582-3","article-title":"Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response","volume":"17","author":"Magbanua","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib80","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jama.2011.593","article-title":"A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer","volume":"305","author":"Hatzis","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e27011_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1334744","article-title":"Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1beta in tumor-associated macrophages","volume":"6","author":"Kersten","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2024.e27011_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251163","article-title":"Clinical evaluation of BCL-2\/XL levels pre- and post- HER2-targeted therapy","volume":"16","author":"Zoeller","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e27011_bib83","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1200\/JCO.2005.04.7019","article-title":"Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer","volume":"24","author":"Thuerigen","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib84","first-page":"21","article-title":"Prognostic significance of interferon-gamma and its signaling pathway in early breast cancer depends on the molecular subtypes","author":"Heimes","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e27011_bib85","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1158\/1078-0432.CCR-17-1535","article-title":"Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts","volume":"23","author":"Lundberg","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib86","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jnci\/djj052","article-title":"Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis","volume":"98","author":"Sotiriou","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.heliyon.2024.e27011_bib87","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.neo.2014.05.007","article-title":"Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance","volume":"16","author":"Putluri","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.heliyon.2024.e27011_bib88","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.onc.1209920","article-title":"A gene-expression signature to predict survival in breast cancer across independent data sets","volume":"26","author":"Naderi","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.heliyon.2024.e27011_bib89","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ccr.2006.10.009","article-title":"Genomic and transcriptional aberrations linked to breast cancer pathophysiologies","volume":"10","author":"Chin","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2024.e27011_bib90","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1200\/JCO.2006.05.6861","article-title":"Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer","volume":"24","author":"Hess","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e27011_bib91","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1073\/pnas.0506230102","article-title":"An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival","volume":"102","author":"Miller","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2024.e27011_bib92","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van 't Veer","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e27011_bib93","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"van de Vijver","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e27011_bib94","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/bcr2753","article-title":"A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer","volume":"12","author":"Yau","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib95","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-06-2765","article-title":"Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series","volume":"13","author":"Desmedt","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e27011_bib96","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-019-0111-0","article-title":"SETER\/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer","volume":"5","author":"Sinn","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.heliyon.2024.e27011_bib97","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-06-2765","article-title":"Consortium T: strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series","volume":"13","author":"Desmedt","year":"2007","journal-title":"Clin. Cancer Res."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024030421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024030421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:35:18Z","timestamp":1782246918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024030421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405844024030421"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27011","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Txnrd1 as a prognosticator for recurrence, metastasis and response to neoadjuvant chemotherapy and radiotherapy in breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e27011"}}